Stock Markets February 23, 2026

Morgan Stanley Names Top Tobacco Stocks as Industry Accelerates Shift to Smoke-Free Products

Philip Morris leads on multi-category execution; Altria positioned for U.S. rollouts as combustible volumes remain dominant

By Avery Klein PM
Morgan Stanley Names Top Tobacco Stocks as Industry Accelerates Shift to Smoke-Free Products
PM

Morgan Stanley ranks leading tobacco companies based on execution in smoke-free alternatives while noting continued reliance on combustibles. Philip Morris International is highlighted for its multi-category strategy and established smoke-free revenue stream, while Altria is noted for U.S.-focused product launches and shifting industry volumes toward disposables and pouches.

Key Points

  • Morgan Stanley ranks tobacco companies based on execution in smoke-free product categories while considering their continued combustible exposure - sectors impacted: tobacco, consumer staples, retail distribution.
  • Philip Morris International leads due to a $17 billion smoke-free business spanning more than 100 markets, a multi-category strategy, and encouraging pilots for its lower-cost BONDS by IQOS platform - sectors impacted: tobacco, consumer goods, international markets.
  • Altria is positioned for U.S. expansion with plans for a national on! PLUS nicotine pouch roll-out after FDA authorization and ongoing combustible product introductions to retain value-focused smokers - sectors impacted: tobacco, U.S. retail, regulatory oversight.

Morgan Stanley has identified leading tobacco companies that it views as best positioned in the sector's move toward smoke-free nicotine delivery systems. The firm's review emphasizes execution in alternative categories - such as heated tobacco, nicotine pouches, and e-vapor devices - while also accounting for each company's continued exposure to traditional combustible cigarettes.

Sector context and methodology

The analysis centers on firms demonstrating measurable progress in smoke-free formats while maintaining scale in combustibles. Morgan Stanley places a premium on companies that both expand choice for consumers switching away from cigarettes and leverage existing sales and distribution infrastructure to accelerate adoption of new products.


1. Philip Morris International

Philip Morris International occupies the top spot in Morgan Stanley's ranking after management updates on the company’s smoke-free growth strategy. Over the past 11 years the company has built a smoke-free business worth $17 billion across more than 100 markets. Despite that progress, combustibles still account for over 80 percent of global nicotine volumes.

Philip Morris pursues a multi-category approach that spans heat-not-burn technology, nicotine pouches, and e-vapor solutions. The firm reports stronger adoption where multiple smoke-free options are available: sales have grown by over 15 percent in 52 markets where multi-category portfolios are present versus roughly 10 percent growth in markets limited to a single smoke-free product category. Morgan Stanley highlights IQOS as an anchor for distribution and merchandising - a presence that can support cross-selling of other smoke-free products such as Zyn and VEEV and that helps create a brand halo when those products are merchandised alongside IQOS.

Philip Morris has also refined its strategy for BONDS by IQOS, a lower-cost heat-not-burn platform intended to appeal to consumers seeking an experience closer to stronger cigarettes. Pilot programs in four Italian cities and in Indonesia have produced encouraging results; the company has signaled it will decide later this year whether to pursue a broader rollout.

In recent company reporting, Philip Morris disclosed fourth-quarter 2025 results with revenue of $10.4 billion, a figure that slightly exceeded analyst forecasts. Stifel called out stronger-than-expected volume growth in the quarter, and both Stifel and UBS subsequently raised their price targets for the stock.


2. Altria

Altria is ranked second by Morgan Stanley after management updates from current CEO Billy Gifford and CEO-elect Sal Mancuso. The company estimates that total U.S. nicotine-equivalent volumes expanded at about 2 percent per year from 2020 through 2025. Over that interval, the share of smoke-free products in industry volumes moved from roughly 20 percent to 50 percent, a shift attributed largely to disposable vaping products and nicotine pouches.

Altria sees substantial opportunity in the U.S. market, citing survey data that nearly half of the 30 million U.S. smokers say they are interested in smoke-free alternatives. The company plans a national launch of on! PLUS nicotine pouches, with distribution expected by the end of the first half following FDA authorization. Early consumer feedback in Florida, North Carolina, and Texas has been described as encouraging. On the combustible front, Altria is preparing to introduce Marlboro Cowboy Cut, a product aimed at retaining value-conscious smokers within the Marlboro portfolio.

Altria's fourth-quarter 2025 results showed revenue of $5.08 billion, which came in ahead of analyst forecasts, while earnings per share of $1.30 were slightly below expectations.


What this means for markets

Morgan Stanley's focus on execution across smoke-free categories highlights differences in go-to-market strength among large tobacco companies. Investors and market observers should watch product rollouts, pilot outcomes, and distribution scale as key drivers of future revenue mix and valuation for companies in the sector.

Risks

  • Combustible products still make up over 80 percent of global nicotine volumes, indicating that a large share of demand remains in traditional cigarettes and could slow the pace of smoke-free adoption - impacts tobacco and consumer staples sectors.
  • The broader rollout of lower-cost platforms such as BONDS by IQOS depends on pilot outcomes and later decisions; pilot results in four Italian cities and Indonesia were encouraging but final expansion is pending a decision later this year - impacts product development and international market strategies.
  • Altria's national distribution of on! PLUS depends on FDA authorization and successful scaling after early regional feedback; regulatory timing and consumer uptake create uncertainty for U.S.-facing revenue forecasts - impacts U.S. retail and regulatory-sensitive sectors.

More from Stock Markets

Bovespa Ends Lower as Financials, Consumer and Real Estate Stocks Weigh on Market Feb 23, 2026 Panama Publishes Court Ruling That Voids CK Hutchison Port Concessions; Maersk to Assume Temporary Control Feb 23, 2026 Consulting Stocks Look Cheap After Sector Selloff; Accenture, ICFI, Booz Allen Among Top Picks Feb 23, 2026 U.S. Equipment Financing Surges in January to Two-Decade High, ELFA Reports Feb 23, 2026 FDA Commissioner Defends Agency Support for mRNA Vaccines While Arguing Taxpayers Should Not Fund Industry R&D Feb 23, 2026